Suicidal behaviors are frequent in mood disorders patients but only a subset of them ever complete suicide. Understanding predisposing factors for suicidal behaviors in high risk populations is of major importance for the prevention and treatment of suicidal behaviors. The objective of this project was to investigate gene expression changes associated with suicide in brains of mood disorder patients by microarrays (Affymetrix HG-U133 Plus2.0) in the dorsolateral prefrontal cortex (DLPFC: 6 Non-suicides, 15 suicides), the anterior cingulate cortex (ACC: 6NS, 9S) and the nucleus accumbens (NAcc: 8NS, 13S). ANCOVA was used to control for age, gender, pH and RNA degradation, with P≤0.01 and fold change±1.25 as criteria for significance. Pathway analysis revealed serotonergic signaling alterations in the DLPFC and glucocorticoid signaling alterations in the ACC and NAcc. The gene with the lowest p-value in the DLPFC was the 5-HT2A gene, previously associated both with suicide and mood disorders. In the ACC 6 metallothionein genes were down-regulated in suicide (MT1E, MT1F, MT1G, MT1H, MT1X, MT2A) and three were down-regulated in the NAcc (MT1F, MT1G, MT1H). Differential expression of selected genes was confirmed by qPCR, we confirmed the 5-HT2A alterations and the global down-regulation of members of the metallothionein subfamilies MT 1 and 2 in suicide completers. MTs 1 and 2 are neuro-protective following stress and glucocorticoid stimulations, suggesting that in suicide victims neuroprotective response to stress and cortisol may be diminished. Our results thus suggest that suicide-specific expression changes in mood disorders involve both glucocorticoids regulated metallothioneins and serotonergic signaling in different regions of the brain.
References
[1]
Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442.
[2]
Nock MK, Borges G, Bromet EJ, Cha CB, Kessler RC, et al. (2008) Suicide and suicidal behavior. Epidemiologic Reviews 30: 133–154.
[3]
WHO (2000) World Health Report 2000. Health Systems: Improving Performance.
[4]
Goldsmith SK, Pellmar TC, Kleinman AM, Bunney WE (2002) Reducing Suicide: A National Imperative. Washington, DC: The National Academy Press.
[5]
Robins E, Murphy GE, Wilkinson RH, Gassner S, Kayes J (1959) Some clinical considerations in the prevention of suicide based on a study of 134 successful suicides. American Journal of Public Health 49: 888–899.
[6]
Barraclough B, Bunch J, Nelson B, Sainsbury P (1974) A hundred cases of suicide: clinical aspects. Br J Psychiatry 125: 355–373.
[7]
Lesage AD, Boyer R, Grunberg F, Vanier C, Morisette R, et al. (1994) Suicide and mental disorders: a case-control study of young men. Am J Psychiatry 151: 1063–1068.
[8]
Bostwick JM, Pankratz VS (2000) Affective disorders and suicide risk: a reexamination. Am J Psychiatry 157: 1925–1932.
Inskip HM, Harris EC, Barraclough B (1998) Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 172: 35–37.
[11]
Guze SB, Robins E (1970) Suicide and primary affective disorders. Br J Psychiatry 117: 437–438.
[12]
Goodwin FK, Jamison KR (1990) Suicide, in Manic-Depressive Illness. Suicide, in Manic-Depressive Illness. pp. 227–244.
[13]
Oquendo MA, Mann JJ (2000) The biology of impulsivity and suicidality. The Psychiatric clinics of North America 23: 11–25.
[14]
Oquendo MA, Baca-Garcia E, Mann JJ, Giner J (2008) Issues for DSM-V: suicidal behavior as a separate diagnosis on a separate axis. Am J Psychiatry 165: 1383–1384.
[15]
Bourne HR, Bunney WE , Colburn RW, Davis JM, Davis JN, et al. (1968) Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients. Lancet 2: 805–808.
[16]
Bunney WE , Davis JM (1965) Norepinephrine in depressive reactions. A review. Arch Gen Psychiat 13: 483–494.
[17]
Mann JJ (2003) Neurobiology of suicidal behaviour. Nature reviews Neuroscience 4: 819–828.
[18]
Jokinen J, Nordstrom AL, Nordstrom P (2009) CSF 5-HIAA and DST non-suppression–orthogonal biologic risk factors for suicide in male mood disorder inpatients. Psychiatr Res 165: 96–102.
[19]
Bunney WE Jr, Fawcett JA (1965) Possibility of a Biochemical Test for Suicidal Potential: An Analysis of Endocrine Findings Prior to Three Suicides. Arch Gen Psychiat 13: 232–239.
[20]
Bunney WE Jr, Fawcett J, Davis JM, Gifford S (1969) Further evaluation of urinary 17-hydroxycorticosteroids in suicidal patients. Arch Gen Psychiat 21: 138–150.
[21]
Gross-Isseroff R, Biegon A, Voet H, Weizman A (1998) The suicide brain: a review of postmortem receptor/transporter binding studies. Neuroscience and biobehavioral reviews 22: 653–661.
[22]
Lopez JF, Vazquez DM, Chalmers DT, Watson SJ (1997) Regulation of 5-HT receptors and the hypothalamic-pituitary-adrenal axis. Implications for the neurobiology of suicide. Annals of the New York Academy of Sciences 836: 106–134.
[23]
McGowan PO, Sasaki A, D’Alessio AC, Dymov S, Labonte B, et al. (2009) Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nature Neuroscience 12: 342–348.
[24]
Sequeira A, Turecki G (2006) Genome wide gene expression studies in mood disorders. OMICS 10: 444–454.
[25]
Sibille E, Arango V, Galfalvy HC, Pavlidis P, Erraji-Benchekroun L, et al. (2004) Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacol 29: 351–361.
[26]
Sequeira A, Gwadry FG, Ffrench-Mullen JM, Canetti L, Gingras Y, et al. (2006) Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 63: 35–48.
[27]
Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, et al. (2007) Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatr.
[28]
Thalmeier A, Dickmann M, Giegling I, Schneider B, Hartmann M, et al. (2008) Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. The international journal of neuropsychopharmacology 11: 217–228.
[29]
Tochigi M, Iwamoto K, Bundo M, Sasaki T, Kato N, et al. (2008) Gene expression profiling of major depression and suicide in the prefrontal cortex of postmortem brains. Neuroscience Research 60: 184–191.
[30]
Kim S, Choi KH, Baykiz AF, Gershenfeld HK (2007) Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genomics 8: 413.
[31]
Sequeira A, Klempan T, Canetti L, Ffrench-Mullen J, Benkelfat C, et al. (2007) Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatr 12: 640–655.
[32]
Yanagi M, Shirakawa O, Kitamura N, Okamura K, Sakurai K, et al. (2005) Association of 14–3-3 epsilon gene haplotype with completed suicide in Japanese. Journal of Human Genetics 50: 210–216.
[33]
Garbett K, Gal-Chis R, Gaszner G, Lewis DA, Mirnics K (2008) Transcriptome alterations in the prefrontal cortex of subjects with schizophrenia who committed suicide. Neuropsychopharmacologia Hungarica 10: 9–14.
[34]
Kelly TM, Mann JJ (1996) Reliability of DSM-III-R diagnosis by psychological autopsy: a comparison with clinician antemortem diagnosis. Acta Psychait Scand 94: 337–343.
[35]
Wester P, Bateman DE, Dodd PR, Edwardson JA, Hardy JA, et al. (1985) Agonal status affects the metabolic activity of nerve endings isolated from postmortem human brain. Neurochem Pathol 3: 169–180.
[36]
Barton AJL, Pearson RCA, Najlerahim A, Harrison PJ (1993) Pre-Postmortem influences on brain RNA. J Neurochem 61: 1–11.
[37]
Atz M, Walsh D, Cartagena P, Li J, Evans S, et al. (2007) Methodological considerations for gene expression profiling of human brain. J Neurosci Methods 163: 295–309.
[38]
Vawter MP, Tomita H, Meng F, Bolstad B, Li J, et al. (2006) Mitochondrial-related gene expression changes are sensitive to agonal-pH state: implications for brain disorders. Mol Psychiatry 615:
[39]
Li JZ, Vawter MP, Walsh DM, Tomita H, Evans SJ, et al. (2004) Systematic changes in gene expression in postmortem human brains associated with tissue pH and terminal medical conditions. Hum Mol Genet 13: 609–616.
[40]
Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, et al. (2004) Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain. Biol Psychiatry 55: 346–352.
[41]
Jones EG, Hendry SH, Liu XB, Hodgins S, Potkin SG, et al. (1992) A method for fixation of previously fresh-frozen human adult and fetal brains that preserves histological quality and immunoreactivity. J Neurosc Methods 44: 133–144.
[42]
Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307–315.
[43]
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome biology 3: RESEARCH0034.
[44]
Cowburn RF, Marcusson JO, Eriksson A, Wiehager B, O’Neill C (1994) Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res 633: 297–304.
[45]
Bunney WE, Bunney BG (2000) Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacol 22: 335–345.
[46]
Sequeira A, Kim C, Seguin M, Lesage A, Chawky N, et al. (2003) Wolfram syndrome and suicide: Evidence for a role of WFS1 in suicidal and impulsive behavior. Am J Med Genet B Neuropsychiatr Genet 119: 108–113.
[47]
Swift M, Swift RG (2005) Wolframin mutations and hospitalization for psychiatric illness. Mol Psychiatr 10: 799–803.
[48]
Swift RG, Sadler DB, Swift M (1990) Psychiatric findings in Wolfram syndrome homozygotes. Lancet 336: 667–669.
[49]
Serretti A, Drago A, De Ronchi D (2007) HTR2A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Current medicinal chemistry 14: 2053–2069.
[50]
McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, et al. (2006) Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. American Journal of Human Genetics 78: 804–814.
[51]
Stanley M, Mann JJ (1983) Increase serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1: 214–216.
[52]
Turecki G, Briere R, Dewar K, Antonetti T, Lesage AD, et al. (1999) Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 156: 1456–1458.
[53]
Hrdina PD, Du L (2001) Levels of serotonin receptor 2A higher in suicide victims? Am J Psychiatry 158: 147–148.
[54]
Pandey GN, Dwivedi Y, Rizavi HS, Ren X, Pandey SC, et al. (2002) Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am J Psychiatry 159: 419–429.
[55]
Shelton RC, Sanders-Bush E, Manier DH, Lewis DA (2009) Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158: 1406–1415.
[56]
Stockmeier CA, Dilley GE, Shapiro LA, Overholser JC, Thompson PA, et al. (1997) Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology 16: 162–173.
[57]
Gross-Isseroff R, Salama D, Israeli M, Biegon A (1990) Autoradiographic analysis of [3H]ketanserin binding in the human brain postmortem: effect of suicide. Brain Res 507: 208–215.
[58]
Rosel P, Arranz B, San L, Vallejo J, Crespo JM, et al. (2000) Altered 5-HT(2A) binding sites and second messenger inositol trisphosphate (IP(3)) levels in hippocampus but not in frontal cortex from depressed suicide victims. Psychiatry Res 99: 173–181.
[59]
Underwood MD, Kassir SA, Bakalian MJ, Galfalvy H, Mann JJ, et al. (2011) Neuron density and serotonin receptor binding in prefrontal cortex in suicide. Int J Neuropsychopharmacol 1–13.
[60]
Young LT, Li PP, Kish SJ, Siu Po K, Kamble A, et al. (1993) Cerebral cortex Gsα protein levels and forskolin-stimulated cyclic AMP formation are increased in bipolar affective disorder. J Neurochem 61: 890–898.
[61]
Rahman S, Li PP, Young LT, Kofman O, Kish SJ, et al. (1997) Reduced [3H]cyclic AMP binding in postmortem brain from subjects with bipolar affective disorder. J Neurochem 68: 297–304.
[62]
Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT (1999) G Protein-coupled cyclic AMP signaling in postmortem brain of subjects with mood disorders: effects of diagnosis, suicide, and treatment at the time of death. J Neurochem 73: 1121–1126.
[63]
Dwivedi Y, Rao JS, Rizavi HS, Kotowski J, Conley RR, et al. (2003) Abnormal expression and functional characteristics of cyclic adenosine monophosphate response element binding protein in postmortem brain of suicide subjects. Arch Gen Psychiat 60: 273–282.
[64]
Wann BP, D’Anjou B, Bah TM, Webster HH, Godbout R, et al. (2009) Effect of olfactory bulbectomy on adenylyl cyclase activity in the limbic system. Brain Research Bulletin 79: 32–36.
[65]
Coyle P, Philcox JC, Carey LC, Rofe AM (2002) Metallothionein: the multipurpose protein. Cellular and molecular life sciences 59: 627–647.
[66]
Pedersen MO, Jensen R, Pedersen DS, Skjolding AD, Hempel C, et al. (2009) Metallothionein-I+II in neuroprotection. Biofactors 35: 315–325.
[67]
Kramer KK, Zoelle JT, Klaassen CD (1996) Induction of metallothionein mRNA and protein in primary murine neuron cultures. Toxicology and Applied Pharmacology 141: 1–7.
[68]
Kramer KK, Liu J, Choudhuri S, Klaassen CD (1996) Induction of metallothionein mRNA and protein in murine astrocyte cultures. Toxicology and Applied Pharmacology 136: 94–100.
[69]
Gasull T, Giralt M, Hernandez J, Martinez P, Bremner I, et al. (1994) Regulation of metallothionein concentrations in rat brain: effect of glucocorticoids, zinc, copper, and endotoxin. The American journal of physiology 266: E760–E767.
[70]
Hidalgo J, Belloso E, Hernandez J, Gasull T, Molinero A (1997) Role of Glucocorticoids on Rat Brain Metallothionein-I and -III Response to Stress. Stress 1: 231–240.
[71]
Hidalgo J, Garcia A, Oliva AM, Giralt M, Gasull T, et al. (1994) Effect of zinc, copper and glucocorticoids on metallothionein levels of cultured neurons and astrocytes from rat brain. Chemico-biological interactions 93: 197–219.
[72]
Zheng H, Berman NE, Klaassen CD (1995) Chemical modulation of metallothionein I and III mRNA in mouse brain. Neurochem Int 27: 43–58.
[73]
Hidalgo J, Aschner M, Zatta P, Vasak M (2001) Roles of the metallothionein family of proteins in the central nervous system. Brain Research Bulletin 55: 133–145.
[74]
Jacob ST, Ghoshal K, Sheridan JF (1999) Induction of metallothionein by stress and its molecular mechanisms. Gene Expression 7: 301–310.
[75]
Ghoshal K, Wang Y, Sheridan JF, Jacob ST (1998) Metallothionein induction in response to restraint stress. Transcriptional control, adaptation to stress, and role of glucocorticoid. The J Biolog Chem 273: 27904–27910.
[76]
Karin M, Haslinger A, Holtgreve H, Richards RI, Krauter P, et al. (1984) Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-IIA gene. Nature 308: 513–519.
[77]
Kelly EJ, Sandgren EP, Brinster RL, Palmiter RD (1997) A pair of adjacent glucocorticoid response elements regulate expression of two mouse metallothionein genes. Proceedings of the National Academy of Sciences of the United States of America 94: 10045–10050.
[78]
Chung RS, Penkowa M, Dittmann J, King CE, Bartlett C, et al. (2008) Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. The J Biolog Chem 283: 15349–15358.
[79]
Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, et al. (2010) Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatr.
[80]
Bunney WE Jr, Mason JW, Hamburg DA (1965) Correlations Between Behavioral Variables and Urinary 17-Hydroxycorticosteroids in Depressed Patients. Psychosomatic Medicine 27: 299–308.
[81]
Vreeburg SA, Hoogendijk WJ, van PJ, DeRijk RH, Verhagen JC, et al. (2009) Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiat 66: 617–626.
[82]
Lopez-Duran NL, Kovacs M, George CJ (2009) Hypothalamic-pituitary-adrenal axis dysregulation in depressed children and adolescents: A meta-analysis. Psychoneuroendocrinology.
[83]
Cowen PJ (2009) Not fade away: the HPA axis and depression. Psychological Medicine 1–4.
[84]
Brent DA, Perper JA, Goldstein CE, Kolko DJ, Allan MJ, et al. (1988) Risk factors for adolescent suicide. A comparison of adolescent suicide victims with suicidal inpatients. Arch Gen Psychiat 45: 581–588.
[85]
Greydanus DE, Calles J Jr (2007) Suicide in children and adolescents. Primary care 34: 259–273.
[86]
Chang X, Jin T, Chen L, Nordberg M, Lei L (2009) Metallothionein I isoform mRNA expression in peripheral lymphocytes as a biomarker for occupational cadmium exposure. Experimental biology and medicine 234: 666–672.